Biognosys
Latest round
- Series A
Last raised
- Oct 2011
Total raised
- $3M
Investors
- 3
About Biognosys
Biognosys AG, founded in 2008 and headquartered in Dietikon, Switzerland, focuses on advanced proteomics solutions. The company has undergone a strategic shift by being acquired by Bruker Corporation, enhancing its capabilities in pharmacoproteomics.5 million to expand its operations.Biognosys specializes in next-generation proteomics solutions aimed at advancing biomarker discovery and drug development. Their core product offerings include a suite of software solutions such as Spectronaut®, which supports data-independent acquisition (DIA) proteomics; SpectroDive™ for targeted proteomics; SpectroMine™ designed for data-dependent acquisition (DDA) proteomics; and the QC tool QuiC™. These software solutions enable researchers across the pharmaceutical and biotech sectors to obtain unbiased biological insights from various samples, including tissue and biofluids. Additionally, Biognosys provides peptide kits and reagents, such as the PQ500™ Reference Peptides for plasma proteomics quantification and iRT kits for quality control, facilitating in-house proteomics research.Biognosys generates revenue through a combination of contract research services, software licensing, and the sale of peptide kits and reagents. The company typically engages in B2B transactions with pharmaceutical and biotech firms, offering both subscription-based access to their software products and one-time purchase options for their reagents and kits. These partnerships may include long-term agreements for the use of their patented platforms, particularly in high-throughput proteomics research, allowing clients to conduct extensive studies on drug targets and biomarkers. Each software solution is offered under specific licensing terms, while reagents are sold individually or as part of bundled kits, enhancing accessibility for researchers. The acquisition will enable the company to accelerate the launch of new products designed specifically for market needs and enhance its operational capabilities in providing proteomics solutions.
Who invested in Biognosys
3 investors across 2 rounds
See all investors in Biognosys
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biognosys
Who invested in Biognosys?
Biognosys has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biognosys raised?
Biognosys has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Biognosys last raise money?
Biognosys's most recent round on record is a Series A, in Oct 2011.
What does Biognosys do?
Biognosys AG, founded in 2008 and headquartered in Dietikon, Switzerland, focuses on advanced proteomics solutions.
Where is Biognosys headquartered?
Biognosys is headquartered in Dietikon, Switzerland.
Which VCs invest in companies like Biognosys?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Biognosys's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Biognosys? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.